Inflammatory Biomarker Panels and Sepsis Prognosis in Intensive Care Cohorts

Abstract

Sepsis remains a leading cause of mortality and critical illness worldwide, characterized by a dysregulated host response to infection that precipitates life-threatening organ dysfunction. Traditional approaches to diagnosing and prognosticating sepsis have relied heavily on clinical scoring systems and single biological markers, which often fail to capture the complex, highly heterogeneous pathophysiological processes underlying the condition. This prospective cohort study investigates the prognostic utility of a multidimensional inflammatory biomarker panel in intensive care unit patients diagnosed with sepsis. Over a continuous twenty-four-month period, adult patients meeting the Third International Consensus Definitions for Sepsis and Septic Shock were enrolled across multiple academic medical centers. A comprehensive panel comprising interleukin-6, interleukin-10, tumor necrosis factor-alpha, soluble urokinase plasminogen activator receptor, and procalcitonin was measured at baseline, day three, and day seven following intensive care admission. The primary outcome was twenty-eight-day all-cause mortality. Utilizing advanced multivariable Cox proportional hazards regression and machine learning-derived composite scoring, the integrated biomarker panel demonstrated significant superiority over standard clinical assessments and single-marker approaches in predicting both short-term mortality and the trajectory of multi-organ failure. The findings suggest that dynamic profiling of host immune responses via composite biomarker panels can substantially enhance risk stratification, thereby facilitating more precise and timely therapeutic interventions in critically ill cohorts.